Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
Zhiqiang Ku(Brown Foundation), Zhiqiang An(Xiamen University), Kevin B. Carlin(IGM Biosciences (United States)), Xiaohua Ye(Energetiq Technology (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Yang Liu(The University of Texas Medical Branch at Galveston), Sachi Rahman(IGM Biosciences (United States)), Dean Ng(IGM Biosciences (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Vineet D. Menachery(Emory University), Bruce A. Keyt, Sujit Biswas(University of Houston), Wei Xiong(Houston Methodist), Elizabeth J. Haanes(IGM Biosciences (United States)), Junquan Liu(Brown Foundation), Deepal Pandya(IGM Biosciences (United States)), Ningyan Zhang(Brown Foundation), Hui Deng(Guangzhou University of Chinese Medicine), Hang Su(Brown Foundation), Jing Zou(The University of Texas Medical Branch at Galveston), Xinli Liu(University of Houston), Yu-An Cao(IGM Biosciences (United States)), Xuping Xie(The University of Texas Medical Branch at Galveston), Antonio E. Muruato(The University of Texas Medical Branch at Galveston), Paul R. Hinton(IGM Biosciences (United States))
Cited by 186
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k